Press Release
Akebia Prevails in Two Additional European Patent Disputes
"We are pleased with the outcome of this week's proceedings in
The
In other news today, Akebia announced that the Company granted options
to purchase 200,000 shares of Akebia's common stock to
About Vadadustat
Vadadustat is an oral, investigational hypoxia-inducible factor (HIF)
stabilizer currently in Phase 3 development for the treatment of anemia
related to chronic kidney disease. Vadadustat exploits the same
mechanism of action used by the body to adapt naturally to lower oxygen
availability associated with a moderate increase in altitude. At higher
altitudes, the body responds to lower oxygen availability with increased
production of HIF, which coordinates the interdependent processes of
iron mobilization and erythropoietin production to increase red blood
cell production and, ultimately, improve oxygen delivery. Vadadustat has
not been approved by the
About Anemia Associated with CKD
Anemia results from the body's inability to coordinate red blood cell production in response to lower oxygen levels due to the progressive loss of kidney function with inadequate erythropoietin production. Left untreated, anemia significantly accelerates patients' overall deterioration of health with increased morbidity and mortality. Anemia is currently treated with injectable recombinant erythropoiesis stimulating agents, which are associated with inconsistent hemoglobin responses and well-documented safety risks. The prevalence of anemia increases with the severity of CKD and is higher in people with CKD who are over age 60.
About
Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements include those about Akebia's strategy, future
plans and prospects, including statements regarding the potential
indications and benefits of vadadustat, and the potential
commercialization of vadadustat. The words "anticipate," "appear,"
"believe," "estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could," "should,"
"continue," and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Each forward-looking statement is
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such statement,
including the risk that existing preclinical and clinical data may not
be predictive of the results of ongoing or later clinical trials; the
ability of Akebia to successfully complete the clinical development
program for vadadustat; the funding required to develop Akebia's product
candidates and operate the company, and the actual expenses associated
therewith; the actual costs incurred in the global development program
for vadadustat, including the Phase 3 studies, and the availability of
financing to cover such costs; the timing of any additional studies
initiated by Akebia or its collaborators for vadadustat; the timing and
content of decisions made by regulatory authorities; the rate of
enrollment in clinical studies of vadadustat; the actual time it takes
to initiate and complete clinical studies; the success of competitors in
developing product candidates for diseases for which Akebia is currently
developing its product candidates; and Akebia's ability to obtain,
maintain and enforce patent and other intellectual property protection
for vadadustat around the world. Other risks and uncertainties include
those identified under the heading "Risk Factors" in Akebia's Report on
Form 10-Q for the quarter ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20170605005308/en/
Akebia:
SVP, Corporate
Communications and Investor Relations
tmcneely@akebia.com
Source:
News Provided by Acquire Media
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax